Galectin-3 Expression in Benign and Malignant Skin Diseases With Epidermal Hyperplasia

Galectin-3 has been suggested relative to tumor genesis, progression, and metastasis in basal cell carcinoma and squamous cell carcinoma that are the most common skin cancers characterized by malignant epidermal proliferation. In this study, we evaluated galectin-3 expression in seborrheic keratosis...

Full description

Saved in:
Bibliographic Details
Published inThe American journal of dermatopathology Vol. 39; no. 10; p. 738
Main Authors Jiang, Ze-Xin, Tan, Guo-Zhen, Shi, Zhen-Rui, Zhang, Yu-Ping, Han, Yan-Fang, Wang, Liangchun
Format Journal Article
LanguageEnglish
Published United States 01.10.2017
Subjects
Biomarkers - analysis
Epidermis - metabolism
Epidermis - pathology
Galectin 3 - analysis
Galectin 3 - biosynthesis
Humans
Hyperplasia - metabolism
Hyperplasia - pathology
Keratinocytes - metabolism
Keratinocytes - pathology
Skin Diseases - metabolism
Skin Diseases - pathology
Online AccessGet more information

Cover

More Information
Summary:Galectin-3 has been suggested relative to tumor genesis, progression, and metastasis in basal cell carcinoma and squamous cell carcinoma that are the most common skin cancers characterized by malignant epidermal proliferation. In this study, we evaluated galectin-3 expression in seborrheic keratosis, keratoacanthoma, and infectious diseases including verruca vulgaris, condyloma acuminatum, and chromoblastomycosis that are pathologically featured by benign epidermal proliferation. Galectin-3 expression was shown by immunohistochemical staining and quantified using the Image Pro Plus V6.0. We found that galectin-3 distributed evenly in normal skin around the body decreased significantly in all selected diseases compared with healthy controls, but it was comparable among each disease. These findings imply that galectin-3 do not differentiate between benign and malignant proliferation of keratinocytes.
ISSN:1533-0311
DOI:10.1097/DAD.0000000000000781